Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has
Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH LA JOLLA, Calif. , April 8, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced
LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2018
LA JOLLA, Calif. , March 15, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright , Chief Research and Development
LA JOLLA, Calif. , Jan. 7, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as a clinical candidate for the treatment of
No Adverse or Other Significant Findings to Date Across All Dose Groups Tested Data Package to Be Submitted to FDA to Support Potential Resumption of Phase 1 Clinical Study LA JOLLA, Calif. , Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused
Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of
$47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has
LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from ATHENA, its global natural history of disease
